A United Kingdom haemophilia centre doctors' organization guideline approved by the British committee for standards in haematology: Guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

British Journal of Haematology

Volumn 149, Issue 4, 2010, Pages 498-507

  Richards, Michael ^a,h   Williams, Michael ^b   Chalmers, Elizabeth ^c   Liesner, Ri ^d   Collins, Peter ^e   Vidler, Vicky ^f   Hanley, John ^g  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^f SHEFFIELD CHILDREN S HOSPITAL   (United Kingdom)

^g NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Adult; Child; Factor VIII; Haemophilia A; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE;

BREAKTHROUGH BLEEDING; CLINICAL ASSESSMENT; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG CHOICE; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG INDICATION; EVIDENCE BASED MEDICINE; FAMILY COUNSELING; HEMARTHROSIS; HEMOPHILIA A; HOME CARE; HUMAN; LABORATORY TEST; MEDICAL LITERATURE; MEDICAL SOCIETY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; QUALITY OF LIFE; RADIOGRAPHY; REVIEW; SECONDARY PREVENTION; TREATMENT DURATION; UNITED KINGDOM;

ADULT; CHILD; COAGULANTS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; FACTOR VIII; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; YOUNG ADULT;

EID: 77951681450     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08139.x     Document Type: Review

References (65)

1. Ahlberg, A. (1965) Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculoskeletal manifestations of haemophilia A and B. Acta Orthopaedica Scandinavica. Supplementum, 77, 3 132.
2. Ahnstrom, J., Berntorp, E., Lindvall, K. Bjorkman, S. (2004) A 6 yr follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia, 10, 689 697. (Pubitemid 40028584)
3. Aronstam, A., Arblaster, P.G., Rainsford, S.G., Turk, P., Slattery, M., Alderson, M.R., Hall, D.E. Kirk, P.J. (1976) Prophylaxis in haemophilia: a double-blind controlled trial. British Journal of Haematology, 33, 81 90.
4. Astermark, J. (2003) When to start and when to stop primary prophylaxis in patients with severe haemophilia. Haemophilia, 9 (Suppl. 1 32 36. (Pubitemid 36622047)
5. Astermark, J., Petrini, P., Tengborn, L., Schulman, S., Ljung, R. Berntrop, E. (1999) Primary prophylaxis in severe haemophilia should be started at an early age but can be individualised. British Journal of Haematology, 105, 1109 1113. (Pubitemid 29309124)
6. Atkins, D., Best, D., Briss, P.A., Eccles, M., Falck-Ytter, Y., Flottorp, S., Guyatt, G.H., Harbour, R.T., Haugh, M.C., Henry, D., Hill, S., Jaeschke, R., Leng, G., Liberati, A., Magrini, N., Mason, J., Middleton, P., Mrukowicz, J., O'Connell, D., Oxman, A.D., Phillips, B., Schünemann, H.J., Edejer, T.T., Varonen, H., Vist, G.E., Williams, J.W., Jr. Zaza, S. GRADE Working Group (2004) Grading quality of evidence and strength of recommendations. BMJ, 328, 1490 1494.
7. van den Berg, H.M., Fischer, K., Mauser-Bunschoten, E.P., Beek, F.J.A., Roosendaal, G., van der Bom, J.G. Nieuwenhuis, H.K. (2001) Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. British Journal of Haematology, 112, 561. (Pubitemid 32222823)
8. Bjorkman, S. (2003) Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia, 9 (Suppl. 1 101 110. (Pubitemid 36622057)
9. Bjorkman, S. Berntorp, E. (2001) Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clinical Pharmacokinetics, 40, 815 832. (Pubitemid 33095998)
10. Blanchette, V.S., Shapiro, A.D., Liesner, R.J., Hernández Navarro, F., Warrier, I., Schroth, P.C., Spotts, G. Ewenstein, B.M. rAHF-PFM Clinical Study Group (2008) Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. Journal Thrombosis and Haemostasis, 6, 1319 1326. (Pubitemid 352016311)
11. Blanchette, V.S., Babyn, P., Chan, A., Card, R., Demers, C., Gill, K., Israels, S., Klaassen, R., Laferriere, N., Lillicrap, D., Luke, K., McLimont, M., Pai, M., Poon, M.C., Price, V., Rivard, G.E., Robinson, S., Steele, M., Wu, J.K.M. Feldman, B.M. (2009) Long term (10 year) results from the Canadian hemophilia primary prophylaxis study. Journal of Thrombosis and Haemostasis, 7 (Suppl. 2 54 55. Abstract AS-WE-003.
12. Carlsson, M., Berntorp, E., Bjorkman, S., Lethagen, S. Ljung, R. (1997) Improved cost-effectiveness by pharmacokinetic dosing of factor VIII in prophylactic treatment of haemophilia A. Haemophilia, 3, 96 101. (Pubitemid 27187173)
13. Collins, P., Fischer, K., Blanchette, V.S., Björkman, S., Oh, M., Schroth, P., Casey, K.M., Spotts, G., Fritsch, S. Ewenstein, B.M. (2008a) Effect of Normal Variation in Factor VIII Pharmacokinetics on Prophylactic Dosing Requirements in Severe Classical Hemophilia. Blood, 112, Abstract 1222.
14. Collins, P., Faradji, A., Morfini, M., Enriquez, M.M., Gorina, E., Schwartz, L. Lemm, G. (2008b) Efficacy and Safety of Secondary Prophylactic Versus On-Demand Sucrose-Formulated Recombinant Factor VIII Treatment in Adults with Severe Hemophilia A: results from a 13-Month Crossover Study. Blood, 112, Abstract 516.
15. Collins, P.W., Blanchette, V.S., Fischer, K., Björkman, S., Oh, M., Fritsch, S., Schroth, P., Spotts, G., Astermark, J. Ewenstein, B. rAHF-PFM Study Group (2009) Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. Journal Thrombosis and Haemostasis, 7, 413 420.
16. van Dijk, K., van der Bom, J.G., Lenting, P.J., de Groot, P.G.E., Mauser-Bunschoten, E.P., Roosendaal, G., Grobbee, D.E. van den Berg, H.M. (2005a) Factor VIII half life and clinical phenotype of severe haemophilia A. Haematologica, 90, 494 498. (Pubitemid 40592892)
17. van Dijk, K., Fischer, K., van der Bom, J., Scheibel, E., Ingerslev, J. van den Berg, H. (2005b) Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands British Journal of Haematology, 130, 107 112. (Pubitemid 40979141)
18. Feldman, B.M., Pai, M., Rivard, G.E., Israels, S., Poon, M.-C., Demers, C., Robinson, S., Luke, K.H., Wu, J.K.M., Gill, K., Lillicrap, D., Babyn, P., McLimont, M. Blanchette, V.S. On behalf of the Association of Hemophilia Clinic Directors of Canada Prophylaxis Study Group (2006) Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophila Primary Prophylaxis Study. Journal of Thrombosis Haemostasis, 4, 1228 1236. (Pubitemid 43756699)
19. Fischer, K. van den Berg, M. (2003) Prophylaxis for severe haemophilia: clinical and economical issues Haemophilia. Haemophilia, 9, 376 381. (Pubitemid 36874384)
20. Fischer, K., van der Bom, J.G., Prejs, R., Mauser-Bunschoten, E.P., Roosendaal, G., Grobbee, D.E. van den Berg, H.M. (2001) Discontinuation of prophylactic therapy in severe haemophilia : incidence and effects on outcome. Haemophilia, 7, 544 550. (Pubitemid 34026747)
21. Fischer, K., van der Bom, J.G., Mauser-Bunschoten, E.P., Roosendaal, G., Prejs, R., de Kleijn, P., Grobbee, D.E. van den Berg, M. (2002a) The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood, 99, 2337 2341. (Pubitemid 34525418)
22. Fischer, K., van der Bom, J.G., Molho, P., Negrier, C., Mauser-Bunschoten, E.P., Roosendaal, G., De Kleijn, P., Grobbee, D.E. van den Berg, H.M. (2002b) Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia, 8, 745 752. (Pubitemid 35446626)
23. Fischer, K., van Dijk, K. van den Berg, H.M. (2005) Late prophylaxis for severe hemophilia: effects of prophylaxis started in adulthood. Journal of Thrombosis and Haemostasis, 3 (Suppl. 1 (Abstract OR 205).
24. Fromme, A., Dreeskamp, K., Pollmann, H., Thorwesten, L., Mooren, F.C. Völker, K. (2007) Participation in sports and physical activity of haemophilia patients. Haemophilia, 13, 323 327. (Pubitemid 46746057)
25. Gouw, S.C., van der Bom, J.G. Marijke van den Berg, H. (2007) Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood, 109, 4648 4654. (Pubitemid 46827754)
26. Gringeri, A., Lundin, B., von Mackensen, S., Mantovani, L.G. Mannucci, P.M. (2009) Primary and secondary prophylaxis in children with haemophilia A reduces bleeding frequency and arthropathy development compared to on-demand treatment: a 10-year, randomized, clinical trial. Journal of Thrombosis and Haemostasis, 7 (Suppl. 2 114 115 (Abstract OC-MO-034).
27. Guyatt, G.H., Oxman, A.D., Kunz, R., Vist, G.E., Falck-Ytter, Y. Schünemann, H.J. GRADE Working Group (2008) What is "quality of evidence" and why is it important to clinicians? British Medical Journal, 336, 995 998. (Pubitemid 351656090)
28. Hacker, M.R., Geraghty, S. Manco-Johnson, M. (2001) Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia, 7, 392 396. (Pubitemid 32677658)
29. Herrick, E.K., Nussbaum, R., Holtzman, N.A. Wissow, L. (2004) Asking fathers: a study of psychosocial adaptation. Haemophilia, 10, 582 589. (Pubitemid 39317770)
30. Hilliard, P., Funk, S., Zourikian, N., Bergstrom, B.M., Bradley, C.S., McLimont, M., Manco-Johnson, M., Petrini, P., van den Berg, M. Feldman, B.M. (2006) Hemophilia joint health score reliability study. Haemophilia, 12, 518 525. (Pubitemid 44227596)
31. Hirschman, R.J., Itscoitz, S.B. Shulman, N.R. (1970) Prophylactic treatment of factor VIII deficiency. Blood, 35, 189 194.
32. Kasper, C.K., Dietrich, S.L. Rapaport, S.I. (1970) Hemophilia prophylaxis with factor VIII concentrate. Archives of Internal Medicine, 125, 1004 1009.
33. Kreuz, W., Escuriola-Ettingshausen, C., Funk, M., Schmidt, H. Kornhuber, B. (1998) When should prophylactic treatment in patients with haemophilia A and B start? - The German experience. Haemophilia, 4, 413 417. (Pubitemid 28351856)
34. Lee, M., Morfini, M. Schulman, S. (2001) The design and analysis of pharmacokinetic studies of coagulation factors. Factor VIII/IX SSC-ISTH 2001 recommendations at http:/ http://www.med.unc.edu/isth/fviiipharmaco.htm.
35. Liesner, R.J., Khair, K. Hann, I.M. (1996) The impact of prophylactic treatment on children with severe haemophilia. British Journal of Haematology, 92, 973 978. (Pubitemid 26109507)
36. Lofqvist, T., Nilsson, I.M., Berntorp, E. Petterson, H. (1997) Haemophilia prophylaxis in young patients - a long term follow up. Journal of Internal Medicine, 241, 395 400. (Pubitemid 27244664)
37. Manco-Johnson, M.J., Pettersson, H., Petrini, P., Babyn, P.S., Bergstrom, B.M., Bradley, C.S., Doria, A.S., Feldman, B.M., Funk, S., Hilliard, P., Kilcoyne, R., Lundin, B., Nuss, R., Rivard, G., Schoenmakers, M.A., Van den Berg, M., Wiedel, J., Zourikian, N. Blanchette, V.S. (2004) Physical therapy and imaging outcome measures in a haemophilia population treated with factor prophylaxis: current status and future directions. Haemophilia, 10 (Suppl. 4 88 93. (Pubitemid 40045425)
38. Manco-Johnson, M.J., Abshire, T.C., Shapiro, A.D., Riske, B., Hacker, M.R., Kilcoyne, R., Ingram, J.D., Manco-Johnson, M.L., Funk, S., Jacobson, L., Valentino, L.A., Hoots, W.K., Buchanan, G.R., DiMichele, D., Recht, M., Brown, D., Leissinger, C., Bleak, S., Cohen, A., Mathew, P., Matsunaga, A., Medeiros, D., Nugent, D., Thomas, G.A., Thompson, A.A., McRedmond, K., Soucie, J.M., Austin, H. Evatt, B.L. (2007) Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. New England Journal of Medicine, 357, 535 544. (Pubitemid 47236278)
39. Miners, A.H., Sabin, C.A., Tolley, K.H. Lee, C.A. (1998) Assessing the effectiveness and cost-effectiveness of prophylaxis against bleeding in patients with severe haemophilia and severe von Willebrand disease. Journal of Internal Medicine, 244, 515 522.
40. Morfini, M. (2003) Pharmacokinetics of factor VIII and factor IX. Haemophilia, 9, 94 100. (Pubitemid 36622056)
41. Morfini, M., Mannucci, P.M., Mariani, G., Panicucci, F., Petrucci, F., Baicchi, U., Capitanio, A., Ferrini, P.L. Mandelli, F. (1976) Evaluation of prophylactic replacement therapy in haemophilia B. Scandinavian Journal of Haematology, 16, 41 47.
42. Nilsson, I.M., Blomback, M. Ahlberg, A. (1970) Our experience in Sweden with prophylaxis on haemophilia A. Proc 5th Cong World Fed Hemophilia Montreal 1968. Bibliotheca Haematologica, 34, 111 124.
43. Nilsson, I.M., Hedner, U. Ahlberg, A. (1976) Haemophilia prophylaxis in Sweden. Acta Paediatrica Scandinavica, 65, 129 135.
44. Nilsson, I.M., Berntorp, E., Löfqvist, T. Pettersson, H. (1992) Twenty-five years' experience of prophylactic treatment in severe hemophilia A and B. Journal of Internal Medicine, 232, 25 32.
45. Petrini, P. (2001) What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B? Haemophilia, 7, 99 102. (Pubitemid 32162205)
46. Petrini, P., Lindvall, N., Egberg, N. Blombäck, M. (1991) Prophylaxis with factor concentrates in preventing hemophilic arthropathy. The American Journal of Pediatric Hematology/Oncology, 13, 280 287.
47. Rabiner, S.F. Telfer, F.C. (1970) Home transfusion for patients with hemophilia A. New England Journal of Medicine, 283, 1011 1015.
48. Ramsay, D.M. Parker, A.C. (1973) A trial of prophylactic replacement therapy in hemophilia and Christmas Disease. Journal of Clinical Pathology, 26, 243 247.
49. Richards, M., Altisent, C., Batorova, A., Chambost, H., Dolan, G., de Moerloose, P., Fraga, M., Hermans, C., Karafoulidou, A., Klamroth, R., Lassila, R. Rothschild, C. (2007) Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data Haemophilia, 13, 473 479. (Pubitemid 47337985)
50. Rizza, C.R. Matthews, J.M. (1972) Management of the Hemophilic Child. Archives of Disease in Childhood, 47, 451.
51. Robinson, P.M., Tittley, P. Smiley, R.K. (1967) Prophylactic therapy in classical hemophilia. A preliminary report. Canadian Medical Association Journal, 97, 559 561.
52. Roosendaal, G., Tekoppele, J.M., Vianen, M.E., van den Berg, H.M., Lafeber, F.P. Bijlsma, J.W. (2000) Articular cartilage is more susceptible to blood induced damage at young than at old age. Journal of Rheumatology, 27, 1740 1744. (Pubitemid 30462821)
53. Ross, C., Goldenberg, N.A., Hund, D. Manco-Johnson, M.J. (2009) Athletic participation in severe hemophilia: bleeding and joint outcomes in children on prophylaxis. Pediatrics, 2009, 124.
54. Saba, H.I., Tannenbaum, B., Morelli, G., Azam, R., Atanes, I. Nichols, C. (2000) Factor prophylaxis in the management of adult haemophiliacs. Haemophilia, 6, 276 (Abstract).
55. Schimpf, K., Fischer, B. Rothmann, P. (1977) Hemophilia A prophylaxis with factor VIII concentrate in a home-treatment program: a controlled study. Scandinavian Journal of Haematology. Supplementum, 30, 79 80.
56. Seuser, A., Boehm, P., Kurme, A., Schumpe, G. Kurnik, K. (2007) Orthopaedic issues in sports for persons with haemophilia. Haemophilia, 13 (Suppl 2. (Pubitemid 47034496)
57. Shanbron, E. Thelin, G.M. (1969) Experimental prophylaxis of severe hemophilia with a factor VIII concentrate. Journal of the American Medical Association, 208, 1835 1856.
58. Shapiro, A., Korth-Bradley, J. Poon, M.-C. (2005) Use of pharmacokinetics in the coagulation factor treatment of patients with haemophilia. Haemophilia, 11, 571 582. (Pubitemid 41631591)
59. Smith, P.S., Teutsch, S.M., Shaffer, P.A., Rolka, H. Evatt, B. (1996) Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. Journal of Pediatrics, 129, 424 431. (Pubitemid 27484150)
60. Stobart, K., Iorio, A. Wu, J.K. (2005) Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with haemophilia A or B. The Cochrane Database of Systematic Reviews 2005, Issue 2. Art. No.: CD003429.pub2. DOI:.
61. Tagliaferri, A., Franchini, M., Coppola, A., Rivolta, G.F., Santoro, C., Rossetti, G., Feola, G., Zanon, E., Dragani, A., Iannaccaro, P., Radossi, P. Mannucci, P.M. (2008) Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia, 14, 945 951.
62. Valentino, L.A. (2004) Secondary prophylaxis therapy: what are the benefits, limitations and unknowns? Haemophilia, 10, 147 157.
63. Van Creveld, S. (1969) Prophylaxis of joint hemorrhages in hemophilia. Acta Haematologica, 41, 206 214.
64. Vidler, V. (1999) Teaching parents advanced clinical skills. Haemophilia, 5, 349 353. (Pubitemid 29495712)
65. Witmer, C., Pressley, R., Kulkarni, R., Soucie, J.M. Manno, C.S. (2008) Intracranial Hemorrhage in Patients with Hemophilia in the Prophylaxis Era. Blood (ASH Annual Meeting Abstracts), 112, 3388.